Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQG3CK)

Drug Name
SR-11237 Drug Info
Synonyms
SR 11237; 146670-40-8; SR-11237; SR11237; BMS 649; BMS 188649; CHEMBL112715; 4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dioxolan-2-yl]benzoic acid; 4-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1,3-dioxolan-2-yl]-benzoic acid; UVI 2108; AC1L2RBO; 4-[2-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTHALEN-2-YL)-[1,3]DIOXOLAN-2-YL]-BENZOIC ACID; 4-(2-(5,6,7,8-Tetrahydro-5,5,8,8,-tetramethyl-2-naphthalenyl)-1,3-dioxolan-2-yl)benzoic acid; SCHEMBL2807932; GTPL2809; CTK8F0685; DTXSID10163433
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Terminated [1]
Cross-matching ID
PubChem CID
127019
ChEBI ID
CHEMBL112715
CAS Number
CAS 146670-40-8
TTD Drug ID
DMQG3CK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Retinoic acid receptor RXR-gamma (RXRG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [3]
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [4]
NRX-4204 DMYXOU2 Diabetic complication 5A2Y Phase 2 [5]
IRX4204 DM9SCME Breast cancer 2C60-2C65 Phase 1 [6]
9cUAB-30 DMYKPXJ Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
AGN-34 DM5ECDM Discovery agent N.A. Investigative [8]
LG100754 DMEK4FY Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Retinoic acid receptor RXR-gamma (RXRG) TTH029C RXRG_HUMAN Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2809).
2 Silicon analogues of the RXR-selective retinoid agonist SR11237 (BMS649): chemistry and biology. ChemMedChem. 2009 Jul;4(7):1143-52.
3 Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3.
4 Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
5 DOI: 10.1038/scibx.2010.766
6 Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.Oncotarget.2016 Feb 16;7(7):7469-79.
7 In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab Dispos. 2007 Jul;35(7):1157-64.
8 Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403.
9 Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature. 1996 Oct 3;383(6599):450-3.